Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IVERIC bio, Inc.OPHT · Entity 111416 | SVP, Gen. Counsel, Secretary | January 04, 2018 | January 05, 2018 |
| SELLAS Life Sciences Group, Inc.SLS · Entity 4313 | EVP, Gen. Counsel, Corp. Sec. | January 22, 2024 | January 25, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IVERIC bio, Inc.
Report date January 04, 2018 · Filed January 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,462 |
Ending reported balance
After 2018-01-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-01-04 · Exercise / conversion · Acquired 1,200 · Balance 17,064 F1: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Row 2 · 2018-01-05 · Sale · Disposed 602 · Balance 16,462 F2: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on January 4, 2018. F3: These shares were disposed of in multiple transactions on January 5, 2018 at actual sales prices ranging from $3.16 to $3.19 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-01-03 | Direct | 2,400 |
Reported balance
After 2018-01-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-01-04 · Exercise / conversion · Disposed 1,200 · Balance 2,400 F1: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4: On January 4, 2016, the reporting person was granted an award of 4,800 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units.
F2: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on January 4, 2018.
F3: These shares were disposed of in multiple transactions on January 5, 2018 at actual sales prices ranging from $3.16 to $3.19 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: On January 4, 2016, the reporting person was granted an award of 4,800 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan.
SELLAS Life Sciences Group, Inc.
Report date January 22, 2024 · Filed January 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,225 |
Reported balance
After 2024-01-22 transaction · row 1
1 source rowRow 1 · 2024-01-22 · Grant · Acquired 35,000 · Balance 117,225 F1: The Reporting Person received an award of 35,000 restricted stock units on January 22, 2024, which shall vest as follows: (i) 25% on December 1, 2024 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.52 · Expires 2034-01-22 | Direct | 50,000 |
Reported balance
After 2024-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-22 · Grant · Acquired 50,000 · Balance 50,000 F2: One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person received an award of 35,000 restricted stock units on January 22, 2024, which shall vest as follows: (i) 25% on December 1, 2024 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.
F2: One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2024 Filed Jan 25, 2024 06:03 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001104659-24-006405 · tm243935-9_4seq1.xml · derivative · entry 2 WOOD BARBARA A · CIK 0001220051 · EVP, Gen. Counsel, Corp. Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-01-22 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| January 22, 2024 Filed Jan 25, 2024 06:03 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-006405 · tm243935-9_4seq1.xml · nonDerivative · entry 1 WOOD BARBARA A · CIK 0001220051 · EVP, Gen. Counsel, Corp. Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,225 F1 · shares: The Reporting Person received an award of 35,000 restricted stock units on January 22, 2024, which shall vest as follows: (i) 25% on December 1, 2024 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 16:11 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | OtherClass A Common Stock | 4,119 | $1.08 | $4,448.52 |
DisclosureSEC source: 0001104659-23-124690 · tm2332459-4_4seq1.xml · nonDerivative · entry 1 WOOD BARBARA A · CIK 0001220051 · EVP, Gen. Counsel, Corp. Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,225 F1 · kind: Transaction relates to shares of common stock withheld by SELLAS Life Sciences Group, Inc. (the "Issuer") to cover tax withholding obligations of the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs"). F2 · shares: Represents the number shares of common stock withheld by the Issuer to cover tax withholding obligations of the Reporting Person in connection with the vesting of RSUs. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 17:18 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0001104659-23-010654 · tm235353d9_4seq1.xml · derivative · entry 2 WOOD BARBARA A · CIK 0001220051 · EVP, Gen. Counsel, Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-02-02 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the February 2, 2023 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 17:18 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-010654 · tm235353d9_4seq1.xml · nonDerivative · entry 1 WOOD BARBARA A · CIK 0001220051 · EVP, Gen. Counsel, Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,344 F1 · shares: The Reporting Person received an award of 20,000 restricted stock units on February 2, 2023, which shall vest as follows: (i) 25% on December 1, 2023 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. Read SEC document |
| December 05, 2022 Filed Dec 5, 2022 16:12 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | SaleClass A Common Stock | 2,153 | $2.59 | $5,576.27 |
DisclosureSEC source: 0001104659-22-124565 · tm2232008-1_4seq1.xml · nonDerivative · entry 1 WOOD BARBARA A · CIK 0001220051 · EVP, Gen. Counsel, Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,344 F1 · shares: Represents the number shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 31, 2022 Filed Feb 1, 2022 17:07 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 48,750 | $0.00 Strike: $5.34 | $0.00 |
DisclosureSEC source: 0001104659-22-010401 · tm225088-7_4seq1.xml · derivative · entry 2 WOOD BARBARA A · CIK 0001220051 · EVP, Gen. Counsel, Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 48,750 shares Expires 2032-01-31 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 31, 2022 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| January 31, 2022 Filed Feb 1, 2022 17:07 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-010401 · tm225088-7_4seq1.xml · nonDerivative · entry 1 WOOD BARBARA A · CIK 0001220051 · EVP, Gen. Counsel, Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,028 F1 · shares: The Reporting Person received an award of 13,000 restricted stock units on January 31, 2022, which shall vest as follows: (i) 25% on December 1, 2022 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 17:14 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | SaleCommon Stock | 847 | $6.25 | $5,297.73 |
DisclosureSEC source: 0001104659-21-146422 · tm2134552-5_4seq1.xml · nonDerivative · entry 1 WOOD BARBARA A · CIK 0001220051 · EVP, Gen. Counsel, Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,028 F1 · shares: Represents the number shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reflects the weighted average sale price of the shares of common stock sold. These shares of common stock were sold in multiple transactions at prices ranging from $6.25 to $6.27, inclusive, per share of common stock. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares of common stock sold at each price. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 16:51 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 47,250 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001104659-21-033337 · tm218923d2_4.xml · derivative · entry 2 WOOD BARBARA A · CIK 0001220051 · EVP, Gen. Counsel, Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,250 Underlying: Common Stock · 47,250 shares Expires 2031-03-04 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 4, 2021 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 16:51 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 7,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-033337 · tm218923d2_4.xml · nonDerivative · entry 1 WOOD BARBARA A · CIK 0001220051 · EVP, Gen. Counsel, Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,875 F1 · shares: The Reporting Person received an award of 7,875 restricted stock units on March 4, 2021, which shall vest as follows: (i) 25% on December 1, 2021 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 21:20 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001104659-20-034291 · tm2012902-7_form4.xml · derivative · entry 2 WOOD BARBARA A · CIK 0001220051 · EVP, Gen. Counsel, Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-03-12 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 12, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 21:20 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-034291 · tm2012902-7_form4.xml · nonDerivative · entry 1 WOOD BARBARA A · CIK 0001220051 · EVP, Gen. Counsel, Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · shares: The reporting person received an award of 35,000 restricted stock units on March 12, 2020, which shall vest as follows: (i) 50% on meeting the primary endpoint in Phase 3 REGAL study, provided that if such endpoint is met prior to March 12, 2021, such vesting will not occur until March 12, 2021 and (ii) 50% upon approval by the FDA of galinpepimut-S. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 19:00 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 165,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0000899243-19-008194 · doc4.xml · derivative · entry 1 WOOD BARBARA A · CIK 0001220051 · EVP, Gen. Counsel, Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2029-03-14 F1 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 14, 2019 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 16:30 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001209191-18-020186 · doc4.xml · derivative · entry 1 WOOD BARBARA A · CIK 0001220051 · EVP, Gen. Counsel, Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-03-13 F1 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 14, 2018 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| January 05, 2018 Filed Jan 5, 2018 17:22 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 602 | $3.17 | $1,908.34 |
DisclosureSEC source: 0001104659-18-001015 · a4.xml · nonDerivative · entry 2 WOOD BARBARA A · CIK 0001220051 · SVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,462 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on January 4, 2018. F3 · price: These shares were disposed of in multiple transactions on January 5, 2018 at actual sales prices ranging from $3.16 to $3.19 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 17:22 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-001015 · a4.xml · derivative · entry 3 WOOD BARBARA A · CIK 0001220051 · SVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Underlying: Common Stock · 1,200 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On January 4, 2016, the reporting person was granted an award of 4,800 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 17:22 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 1,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-001015 · a4.xml · nonDerivative · entry 1 WOOD BARBARA A · CIK 0001220051 · SVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| January 03, 2018 Filed Jan 4, 2018 17:09 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 694 | $3.24 | $2,248.56 |
DisclosureSEC source: 0001104659-18-000811 · a4.xml · nonDerivative · entry 2 WOOD BARBARA A · CIK 0001220051 · SVP, General Counsel,Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,864 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on January 2, 2018. F3 · price: These shares were disposed of in multiple transactions on January 3, 2018 at actual sales prices ranging from $3.24 to $3.25 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 17:02 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 5,289 | $3.19 | $16,871.91 |
DisclosureSEC source: 0001104659-18-000568 · a4.xml · nonDerivative · entry 2 WOOD BARBARA A · CIK 0001220051 · SVP,General Counsel,Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,183 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on December 29, 2017. F3 · price: These shares were disposed of in multiple transactions on January 2, 2018 at actual sales prices ranging from $3.10 to $3.25 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:09 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 1,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-000811 · a4.xml · derivative · entry 3 WOOD BARBARA A · CIK 0001220051 · SVP, General Counsel,Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,375 Underlying: Common Stock · 1,375 shares Expires 2025-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On January 2, 2015, the reporting person was granted an award of 5,500 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:09 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 1,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-000811 · a4.xml · nonDerivative · entry 1 WOOD BARBARA A · CIK 0001220051 · SVP, General Counsel,Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 17:02 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 12,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-000568 · a4.xml · derivative · entry 3 WOOD BARBARA A · CIK 0001220051 · SVP,General Counsel,Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,140 shares Expires 2027-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On January 17, 2017, the reporting person was granted an award of 24,280 restricted stock units, which vested with respect to 50% of the shares subject to the award on each of June 30, 2017 and December 29, 2017, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 17:02 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 12,140 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-000568 · a4.xml · nonDerivative · entry 1 WOOD BARBARA A · CIK 0001220051 · SVP,General Counsel,Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| July 05, 2017 Filed Jul 5, 2017 18:33 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 5,119 | $2.58 | $13,207.02 |
DisclosureSEC source: 0001104659-17-043658 · a4.xml · nonDerivative · entry 2 WOOD BARBARA A · CIK 0001220051 · SVP,General Counsel,Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,332 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on June 30, 2017. F3 · price: These shares were disposed of in multiple transactions on July 5, 2017 at actual sales prices ranging from $2.55 to $2.64 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:33 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 12,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-043658 · a4.xml · derivative · entry 3 WOOD BARBARA A · CIK 0001220051 · SVP,General Counsel,Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,140 Underlying: Common Stock · 12,140 shares Expires 2027-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On January 17, 2017, the reporting person was granted an award of 24,280 restricted stock units, which vests with respect to 50% of the shares subject to the award on each of June 30, 2017 and December 29, 2017, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:33 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 12,140 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-043658 · a4.xml · nonDerivative · entry 1 WOOD BARBARA A · CIK 0001220051 · SVP,General Counsel,Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 17:14 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001104659-17-005851 · a4.xml · derivative · entry 1 WOOD BARBARA A · CIK 0001220051 · SVP,General Counsel,Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2027-01-29 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, each of these stock option awards will vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 17:37 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | GrantRestricted Stock Units · Derivative | 24,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-003128 · a4.xml · derivative · entry 1 WOOD BARBARA A · CIK 0001220051 · SVP,General Counsel,Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,280 Underlying: Common Stock · 24,280 shares Expires 2027-01-16 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F2 · derivative.exercise_date: Subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan and the reporting person's employment agreement, the award of restricted stock units will vest with respect to 50% of the shares subject to the award on each of June 30, 2017 and December 29, 2017. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 17:14 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 589 | $4.96 | $2,921.44 |
DisclosureSEC source: 0001104659-17-001235 · a4.xml · nonDerivative · entry 2 WOOD BARBARA A · CIK 0001220051 · SVP,General Counsel,Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,311 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on January 4, 2017. F3 · price: These shares were disposed of in multiple transactions on January 5, 2017 at actual sales prices ranging from $4.90 to $5.04 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 17:14 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-001235 · a4.xml · derivative · entry 3 WOOD BARBARA A · CIK 0001220051 · SVP,General Counsel,Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 1,200 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On January 4, 2016, the reporting person was granted an award of 4,800 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 17:14 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 1,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-001235 · a4.xml · nonDerivative · entry 1 WOOD BARBARA A · CIK 0001220051 · SVP,General Counsel,Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 17:05 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 675 | $4.90 | $3,307.50 |
DisclosureSEC source: 0001104659-17-000645 · a4.xml · nonDerivative · entry 2 WOOD BARBARA A · CIK 0001220051 · SVP, General Counsel,Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on January 2, 2017. F3 · price: These shares were disposed of in multiple transactions on January 3, 2017 at actual sales prices ranging from $4.85 to $4.98 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2017 Filed Jan 4, 2017 17:05 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 1,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000645 · a4.xml · derivative · entry 3 WOOD BARBARA A · CIK 0001220051 · SVP, General Counsel,Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Underlying: Common Stock · 1,375 shares Expires 2025-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On January 2, 2015, the reporting person was granted an award of 5,500 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| January 02, 2017 Filed Jan 4, 2017 17:05 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 1,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-000645 · a4.xml · nonDerivative · entry 1 WOOD BARBARA A · CIK 0001220051 · SVP, General Counsel,Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| December 23, 2016 Filed Dec 27, 2016 17:10 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 746 | $4.92 | $3,670.32 |
DisclosureSEC source: 0001104659-16-163900 · a4.xml · nonDerivative · entry 1 WOOD BARBARA A · CIK 0001220051 · SVP,General Counsel,Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: These shares were disposed of in multiple transactions on December 23, 2016 at actual sales prices ranging from $4.92 to $4.95 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.